La vendita allo scoperto per Sino Biopharmaceutical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Sino Biopharmaceutical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Sino Biopharmaceutical (OTC:SBMFF) Azioni, Report sulle vendite allo scoperto

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

SINO BIOPHARM ORD by Sino Biopharmaceutical Ltd.

Comments

Sino Biopharmaceutical

Vendite allo scoperto

Sino Biopharmaceutical (OTC:SBMFF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO